Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

U.S. District Judge Mark Pittman in Texas issued the sealed order on Wednesday in response to a lawsuit filed in October by a ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk (NVO) stock rises after Q1 2025 results, even after the company cut its outlook as it sees a sales recovery for ...

WW International, formerly known as WeightWatchers, filed for Chapter 11 bankruptcy protection on Tuesday in a bid to cut its ...